A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localised prostate cancer treated with primary radical treatment
Download the following Poster Presentation: A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localised prostate cancer treated with primary radical treatment.
- The Metastatic Assay predicts BF and DM in PCa patients treated with either radical surgery or EBRT.
- This assay may help to select patients at low risk of relapse, who may benefit from an active surveillance approach, and to identify those patients at high risk of metastatic disease for additional treatment aimed at preventing disease recurrence
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.